Reviewing Beyondspring (NASDAQ:BYSI) & Ultragenyx Pharmaceutical (NASDAQ:RARE)

Share on StockTwits

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Beyondspring (NASDAQ:BYSI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ultragenyx Pharmaceutical and Beyondspring, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ultragenyx Pharmaceutical 0 2 9 0 2.82
Beyondspring 0 1 2 0 2.67

Ultragenyx Pharmaceutical presently has a consensus price target of $73.36, indicating a potential upside of 76.65%. Beyondspring has a consensus price target of $41.00, indicating a potential upside of 176.65%. Given Beyondspring’s higher probable upside, analysts plainly believe Beyondspring is more favorable than Ultragenyx Pharmaceutical.

Institutional & Insider Ownership

5.7% of Beyondspring shares are held by institutional investors. 7.8% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Ultragenyx Pharmaceutical has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500. Comparatively, Beyondspring has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and Beyondspring’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ultragenyx Pharmaceutical -470.18% -52.16% -44.50%
Beyondspring N/A -1,169.02% -628.40%

Earnings and Valuation

This table compares Ultragenyx Pharmaceutical and Beyondspring’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ultragenyx Pharmaceutical $51.49 million 46.60 -$197.61 million ($7.39) -5.62
Beyondspring N/A N/A -$54.87 million ($2.42) -6.12

Beyondspring has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Beyondspring is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Ultragenyx Pharmaceutical beats Beyondspring on 8 of the 13 factors compared between the two stocks.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

About Beyondspring

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Strs Ohio Has $21.92 Million Stake in Western Digital Corp
Strs Ohio Has $21.92 Million Stake in Western Digital Corp
Strs Ohio Has $22.13 Million Stock Position in Humana Inc
Strs Ohio Has $22.13 Million Stock Position in Humana Inc
Valeo Financial Advisors LLC Has $104,000 Stock Position in LYFT Inc
Valeo Financial Advisors LLC Has $104,000 Stock Position in LYFT Inc
Strs Ohio Sells 288,000 Shares of Discovery Communications Inc.
Strs Ohio Sells 288,000 Shares of Discovery Communications Inc.
Strs Ohio Has $23.09 Million Position in Waste Management, Inc.
Strs Ohio Has $23.09 Million Position in Waste Management, Inc.
Valeo Financial Advisors LLC Grows Position in Baker Hughes A GE Co
Valeo Financial Advisors LLC Grows Position in Baker Hughes A GE Co


© 2006-2020 Ticker Report